These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26980028)

  • 1. Detection of TERT promoter mutations in primary adenocarcinoma of the urinary bladder.
    Cowan ML; Springer S; Nguyen D; Taheri D; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; Del Carmen Rodriguez Pena M; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Kinzler K; Bivalacqua T; Papadopoulos N; Vogelstein B; Netto GJ
    Hum Pathol; 2016 Jul; 53():8-13. PubMed ID: 26980028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder.
    Cowan M; Springer S; Nguyen D; Taheri D; Guner G; Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Cunha I; Fujita K; Ertoy D; Bivalacqua TJ; Kinzler K; Vogelstein B; Netto GJ; Papadopoulos N
    Mod Pathol; 2016 May; 29(5):511-5. PubMed ID: 26965579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
    Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
    Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
    Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
    Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activating Telomerase
    Zvereva M; Pisarev E; Hosen I; Kisil O; Matskeplishvili S; Kubareva E; Kamalov D; Tivtikyan A; Manel A; Vian E; Kamalov A; Ecke T; Calvez-Kelm FL
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum of genetic mutations in de novo PUNLMP of the urinary bladder.
    Rodriguez Pena MDC; Tregnago AC; Eich ML; Springer S; Wang Y; Taheri D; Ertoy D; Fujita K; Bezerra SM; Cunha IW; Raspollini MR; Yu L; Bivalacqua TJ; Papadopoulos N; Kinzler KW; Vogelstein B; Netto GJ
    Virchows Arch; 2017 Dec; 471(6):761-767. PubMed ID: 28597078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C; Wezel F; Southgate J; Bolenz C
    Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
    Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
    Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer.
    Leão R; Lee D; Figueiredo A; Hermanns T; Wild P; Komosa M; Lau I; Mistry M; Nunes NM; Price AJ; Zhang C; Lipman T; Poyet C; Valtcheva N; Oehl K; Coelho H; Sayyid R; Gomes AM; Prado E Castro L; Sweet J; Vinagre J; Apolónio J; Stephens D; Faleiro I; Fadaak K; Richard PO; Kulkarni G; Zlotta AR; Hamilton RJ; Castelo-Branco P; Tabori U
    Int J Cancer; 2019 Apr; 144(7):1676-1684. PubMed ID: 30350309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.